Mar 22, 2019 / 08:30PM GMT
Operator
Good afternoon, and welcome to the Recro Pharma Investor Conference Call on Friday, March 22, 2019. (Operator Instructions) As a reminder, this conference is being recorded at the company's request.
I would now like to turn the call over to Claudia Styslinger, Investor Relations. You may begin.
Claudia Styslinger -
Good afternoon, and thank you for joining us on today's conference call to discuss the Complete Response Letter received by Recro Pharma from the U.S. Food and Drug Administration regarding its new drug application for IV meloxicam. This is Claudia Styslinger, and I am joined today by Gerri Henwood, President and Chief Executive Officer. In addition, Ryan Lake, Chief Financial Officer, is in the room and will be available during Q&A.
Earlier this afternoon, the company issued a press release announcing that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding the NDA for IV meloxicam. The press release is available on the News & Investors page of Recro's website at recropharma.com.
Recro Pharma Inc Corporate Update Call Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers